{"classes":[{"categories":[{"measurements":[{"comment":"The data are not mature because follow-up for events is not long enough. As such, the median was not reached and the upper bound 95% CI could not be estimated.","groupId":"OG000","lowerLimit":"24.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"DOR was defined at the time from the first assessment indicating PR or better response to the first progression (PD) event based on IMWG criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide (R): 25 mg on days 1-14 orally Subcutaneous Bortezomib (sqV): 1.3 mg/m\\^2 on days 1, 4, 8 and 11 Dexamethasone (d): 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 Stem cell mobilization occurs at the end of Cycle 4. Participants may elect to stop treatment at the end of Induction Cycle 4 and proceed to autologous stem cell transplant (ASCT) with melphalan 200 mg/m\\^2 conditioning, or receive a full 8 cycles of RsqVd induction therapy. RsqVd cycle duration is 21-days.\n\nMaintenance follows with the specific regimen determined by risk category. High-risk participants defined as those with International Staging System (ISS) stage II or stage III disease and/or high-risk cytogenetics including t(4;14), t(4; 16), del(17p) receive sqV of 1.3 mg/m\\^2 on days 1 and 15 in addition to R 10mg (15mg after cycle 3 if tolerated) on days 1-21 of 28-day cycle. Standard-risk participants receive R monotherapy.","id":"OG000","title":"Lenalidomide, Subcutaneous Bortezomib, Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"The analysis population is comprised of participants who achieved partial response.","reportingStatus":"POSTED","timeFrame":"Disease was assessed up to 41.2 months.","title":"Median Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}